Vivos Inc. Short Interest Decreases Significantly

Vivos Inc. (OTCMKTS:RDGL - Get Free Report) experienced a noteworthy decline in short interest during February. By February 15th, short interest had dropped to 5,800 shares, representing a substantial decrease of 67.8% from the total of 18,000 shares noted on January 31st. Given the average daily trading volume of 2,339,200 shares, the current short-interest ratio stands at just 0.0 days.

Vivos Stock Performance

During mid-day trading on a recent Friday, shares of OTCMKTS:RDGL experienced a minor decline, settling at $0.11. A total of 1,037,901 shares changed hands, which is below the average trading volume of 1,362,140. The stock’s 50-day simple moving average is $0.13, as is its 200-day moving average. Currently, Vivos holds a market capitalization of $50.23 million, has a price-to-earnings ratio of -11.07, and a beta of 0.89. The stock has fluctuated over the past year, with a low of $0.05 and a high of $0.26.

About Vivos Inc.

Vivos Inc. is a company focused on radiation oncology. It specializes in creating brachytherapy devices designed for the treatment of non-resectable tumors within the United States. One of its notable products is the yttrium-90 based RadioGel device, which is an injectable particle-gel utilized in brachytherapy for treating cancerous tumors in both humans and animals. Additionally, Vivos has developed IsoPet, aimed at treating solid tumors specifically in animals.

Investment Considerations

Before contemplating an investment in Vivos, it's worth noting that analysis from leading Wall Street experts suggests alternative opportunities. MarketBeat tracks top-performing research analysts who provide stock recommendations to their clients. Presently, Vivos is not included amongst the top five stock picks highlighted by these analysts, which suggests there may be more favorable investment options available.

Those interested in Vivos should proceed with caution and consider reviewing other recommendations to ensure a well-informed investment decision.

Vivos, Stocks, Market